Peptide & Compound Guide
At a glance
| Compound | Tesamorelin |
|---|---|
| Type | Growth-hormone-releasing factor analogue |
| U.S. regulatory context | FDA-approved prescription medicine for a defined indication |
| Evidence level | Established clinical evidence for its approved indication |
| Research area | Excess abdominal fat in adults with HIV and lipodystrophy |
What is Tesamorelin?
Tesamorelin is a peptide medicine that stimulates growth-hormone release. Unlike many compounds grouped online as “research peptides,” tesamorelin has an FDA-approved prescription indication.
What does the research examine?
Its approval and evidence are indication-specific. Research outside the approved population should be described separately from established use.
What has not been established?
Mechanism, biomarker changes, animal findings and early clinical signals are not the same as proof that a compound safely improves meaningful health outcomes. Claims should be matched to the type, size and quality of evidence available.
Safety and regulatory context
Tesamorelin has clinically important contraindications, monitoring considerations and adverse effects that require professional medical oversight.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.